Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Qingluo is a Traditional Chinese Medicine (TCM) herbal formulation developed as a granule for the treatment of active rheumatoid arthritis (RA). Specifically indicated for patients presenting with the Dampness-heat obstruction syndrome (Shi-Re-Bi) according to TCM diagnostic criteria, the formula is designed to clear heat, resolve dampness, and unblock the collaterals. It is currently undergoing clinical evaluation in multicenter, randomized, double-blind, placebo-controlled trials to assess its efficacy and safety in reducing disease activity and improving symptoms in RA patients. The development is led by Yijishan Hospital of Wannan Medical College.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiawei qingluo.